First National Equities Announces Major Divestment, Expansion, and New Entry into Pharma Sector

First National Equities Limited (FNEL) has unveiled a series of major strategic moves, including a significant divestment, expansion of its real estate arm, and a bold entry into Pakistan’s pharmaceutical sector, according to a disclosure sent to the Pakistan Stock Exchange on October 3, 2025. The company’s Board of Directors, alongside approving the annual audited financial statements, has greenlit three key decisions: FNEL has agreed to sell its 20% equity stake, amounting to 10,000 Class-B non-voting shares, in Kingbhai Digisol (Private) Limited for Rs. 280 million. The deal values Kingbhai Digisol at approximately Rs. 1.5 billion, based on an independent assessment. FNEL says this move is part of its strategy to unlock value and redirect capital toward higher-growth opportunities. The Board has approved an investment of up to Rs. 400 million in its subsidiary, FNE Developments (Private) Limited. The investment, which may take the form of equity, loans, or other financial instruments, is aimed at accelerating growth in real estate and infrastructure projects, sectors FNEL sees as having strong recurring revenue potential. FNEL is set to invest up to Rs. 500 million to establish or acquire a pharmaceutical manufacturing facility or company, either independently or in partnership with its subsidiaries or associates. This marks FNEL’s first foray into the pharmaceutical industry, which the company describes as one of Pakistan’s most promising and high-growth sectors. All these decisions are subject to approval by shareholders and regulatory authorities.